Ronald Kingsley, MD
Retina Specialist · Oklahoma City, OKNPI 1962471326
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 37 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Genentech USA, Inc. at 29.1% of the total. Reporting peaked in 2023 at $261 and has fallen 78.9% since, to $55 in 2025.
Across 37 payments — averaging $27.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$294
- Novartis$232
- Merz Pharmaceuticals, LLC$105
- AbbVie$64
- Apellis Pharmaceuticals, Inc.$53
- Genentech, Inc.$52
- plus $208 from 8 others
Across 20 payments — averaging $5185.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$99K
- AstraZeneca$4K
- Novo Nordisk AS$955
What the payments were for
- Travel & lodging$283%
- Food & beverage$98197%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 10 | $294 |
| Novartis | 8 | $232 |
| Merz Pharmaceuticals, LLC | 2 | $105 |
| AbbVie | 4 | $64 |
| Apellis Pharmaceuticals, Inc. | 2 | $53 |
| Genentech, Inc. | 1 | $52 |
| Alcon | 2 | $44 |
| Mallinckrodt Hospital Products Inc. | 2 | $35 |
| Astellas Pharma US Inc | 1 | $34 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Thea Pharma Inc. | 1 | $22 |
| Bausch & Lomb Americas Inc. | 1 | $15 |
| Vyera Pharmaceuticals, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VABYSMO$117
How this compares
Too few retina specialist providers in Oklahomato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 17 | $671 |
| Ketorolac Tromethamine | 12 | $263 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Oklahoma City
- Vinay ShahOklahoma City$95K
- Razek Georges CoussaOklahoma City$10K
- Jordan JohnsonOklahoma City$4K
- Sumit NandaOklahoma City$3K
- Stanley ParkOklahoma City$964
- Robert LeonardOklahoma City$731
- Reagan BradfordOklahoma City$566
- Miguel Cruz PimentelOklahoma City$86
- Sandeep ShahEdmond$24K
- Brian PhelpsEdmond$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.